Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
US Army
Julphar
Fuji
Citi
Queensland Health
Merck
Cipla
Argus Health
Harvard Business School

Generated: October 17, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,340,821

« Back to Dashboard

Claims for Patent: 5,340,821

Title: Composition and method for treating Sjoegren syndrome disease
Abstract:A composition for treating a Sjoegren syndrome disease is disclosed. The composition comprising derivative of spirooxathiolane-quinuclidine of the following formula (I), ##STR1## wherein Z is .dbd.CR.sup.1 R.sup.2, wherein R.sup.1 and R.sup.2 may be the same or different and each represents hydrogen, alkyl, cyclopentyl, cyclohexyl, aryl, diarylmethylol, or alkyl which may be substituted by one or more aryl groups, or an acid addition salt thereof, or an acid addition salt thereof, as an effective component. Especially effective is an administration of a hydrochloric acid addition salt of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine.
Inventor(s): Abe; Nobuaki (Tokyo, JP), Takeshita; Yasuyoshi (Utsunomiya, JP)
Assignee: Snow Brand Milk Products Co., Ltd. (JP)
Application Number:08/088,304
Patent Claims: 1. A method for treating the symptoms of Sjoegren syndrome disease comprising administering to a patient afflicted with the disease an amount of a spirooxathiolane-quinuclide compound having the following formula (I), ##STR4## wherein Z is .dbd.CR.sup.1 R.sup.2, wherein R.sup.1 and R.sup.2 may be the same or different and each represents hydrogen, alkyl, cyclopentyl, cyclohexyl, aryl, diarylmethylol, or alkyl which may be substituted by one or more aryl groups, or an acid addition salt thereof, sufficient to alleviate the symptoms of the disease.

2. The method of claim 1, wherein said spirooxathiolane-quinuclidine compound is a hydrochloric acid addition salt of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine having the following formula (II) ##STR5##

3. The method of claim 2, wherein said hydrochloric addition salt of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine is a cis isomer.

4. The method of claim 1 wherein said composition further comprises a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cipla
McKinsey
Argus Health
Merck
Johnson and Johnson
QuintilesIMS
Healthtrust
Queensland Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot